Cargando…

Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation

Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Next to progressive airway disease, CF is also associated with intestinal inflammation and dysbiosis. Ivacaftor, a CFTR potentiator, has improved pulmonary and nutritional status but i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ooi, Chee Y., Syed, Saad A., Rossi, Laura, Garg, Millie, Needham, Bronwen, Avolio, Julie, Young, Kelsey, Surette, Michael G., Gonska, Tanja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292911/ https://www.ncbi.nlm.nih.gov/pubmed/30546102 http://dx.doi.org/10.1038/s41598-018-36364-6

Ejemplares similares

Gut Microbiota in Children With Cystic Fibrosis: A Taxonomic and Functional Dysbiosis
por: Coffey, Michael J., et al.
Publicado: (2019)

Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator
por: Laselva, Onofrio, et al.
Publicado: (2021)

CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes
por: Lefferts, Juliet W., et al.
Publicado: (2023)

The CFTR Mutation c.3453G > C (D1152H) Confers an Anion Selectivity Defect in Primary Airway Tissue that Can be Rescued by Ivacaftor
por: Laselva, Onofrio, et al.
Publicado: (2020)

Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis
por: Nielsen, Shaun, et al.
Publicado: (2016)

The use of ivacaftor in CFTR mutations resulting in residual functioning protein
por: Guigui, S., et al.
Publicado: (2016)

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
por: Tümmler, Burkhard
Publicado: (2023)

Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass
por: Mouzaki, Marialena, et al.
Publicado: (2023)

Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations
por: Csanády, László, et al.
Publicado: (2019)

Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults
por: Kim, Jeeyeon, et al.
Publicado: (2018)

Structure of ABCB1/P-Glycoprotein in the Presence of the CFTR Potentiator Ivacaftor
por: Barbieri, Alessandro, et al.
Publicado: (2021)

Impact of the CFTR-Potentiator Ivacaftor on Airway Microbiota in Cystic Fibrosis Patients Carrying A G551D Mutation
por: Bernarde, Cédric, et al.
Publicado: (2015)

Investigation of the effects of the CFTR potentiator ivacaftor on human P-glycoprotein (ABCB1)
por: Lingam, Swathi, et al.
Publicado: (2017)

Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment
por: Shaughnessy, Ciaran A., et al.
Publicado: (2021)

Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation
por: Rowe, Steven M., et al.
Publicado: (2013)

Ivacaftor in Omani children with cystic fibrosis caused by p.Ser549Arg CFTR mutation
por: Al Oraimi, Sumaya, et al.
Publicado: (2022)

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
por: Bessonova, Leona, et al.
Publicado: (2018)

Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment
por: Shaughnessy, Ciaran A., et al.
Publicado: (2021)

Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
por: Bacalhau, Mafalda, et al.
Publicado: (2023)

The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurements
por: Char, Jessica E., et al.
Publicado: (2017)

From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis
por: Gramegna, Andrea, et al.
Publicado: (2020)

Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
por: Veit, Guido, et al.
Publicado: (2020)

Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations
por: Hardisty, Gareth R., et al.
Publicado: (2021)

CFTR bearing variant p.Phe312del exhibits function inconsistent with phenotype and negligible response to ivacaftor
por: Raraigh, Karen S., et al.
Publicado: (2022)

Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia
por: Ahmadi, Saumel, et al.
Publicado: (2017)

Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N Mutation
por: Kristensen, Maartje I., et al.
Publicado: (2021)

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor
por: Rubin, Jaime L., et al.
Publicado: (2019)

CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis
por: Sommerburg, Olaf, et al.
Publicado: (2021)

CFTR potentiator ivacaftor protects against noise-induced hair cell loss by increasing Nrf2 and reducing oxidative stress
por: Wu, Fan, et al.
Publicado: (2023)

Gut microbiota signatures in cystic fibrosis: Loss of host CFTR function drives the microbiota enterophenotype
por: Vernocchi, Pamela, et al.
Publicado: (2018)

A Little CFTR Goes a Long Way: CFTR-Dependent Sweat Secretion from G551D and R117H-5T Cystic Fibrosis Subjects Taking Ivacaftor
por: Char, Jessica E., et al.
Publicado: (2014)

Cftr deletion in mouse epithelial and immune cells differentially influence the intestinal microbiota
por: Scull, Callie E., et al.
Publicado: (2022)

The Exocrine Pancreas in Cystic Fibrosis in the Era of CFTR Modulation: A Mini Review
por: McKay, Isabelle R., et al.
Publicado: (2022)

Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022)

Intestinal Inflammation and Alterations in the Gut Microbiota in Cystic Fibrosis: A Review of the Current Evidence, Pathophysiology and Future Directions
por: Tam, Rachel Y., et al.
Publicado: (2022)

Pharmacokinetic and Drug–Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor
por: Garg, Varun, et al.
Publicado: (2019)

Modulation of Gut Microbiota Composition by Serotonin Signaling Influences Intestinal Immune Response and Susceptibility to Colitis
por: Kwon, Yun Han, et al.
Publicado: (2019)

Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome
por: Marsh, Ryan, et al.
Publicado: (2023)

Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial
por: Quittner, Alexandra, et al.
Publicado: (2015)

Non‐pulmonary CFTR‐related symptom improvement with ivacaftor in p.Phe508del/p.Arg117His (7T) cystic fibrosis
por: Kuek, Stephanie L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pq03m2v4alg1egvpqk5sjvffqu